1,721,090 research outputs found
La proteomica in campo cardiovascolare: sfide ed opportunità per la cardiologia del futuro
No full textProteomics is the study of the "proteome", that is the entire protein complement of a genome. However, it is well recognized that the proteome is far more complex than previously suggested by the "one-gene, oneprotein" central dogma of biology. The proteome encompasses all proteins of a cell or organism at a given time, including not only those translated directly from genetic information but also the array of modified proteins arising from alternative splicing of transcripts and post-translational processing, resulting in modifications that have the potential to alter protein structure or biological function. As proteins are involved in virtually every cellular function, control every regulatory mechanism, and are modified in disease states, the proteome dictates the phenotype of the cell and, consequently, the tissue or organ that the cells comprise. This results in a dynamic, ongoing process of protein expression and modifications. The proteome thus consists of information from protein expression, post-translational modifications, processing and turnover, localization and time. Proteomics is aimed at identifying and characterizing these protein changes and, if applied to the field of cardiovascular sciences, it has the potential to reveal those proteins that are associated with pathogenesis and could be potentially used as predictive or prognostic markers. Cardioproteomic is still in its infancy and relatively few cardiovascular diseases have been investigated. However, it has enormously increased our knowledge of the complexity of the myocardium in terms of protein composition at cellular and organelle levels. The cardiac proteome is further complicated by protein post-translational modifications, which may regulate organelle function in physiological and pathological conditions. Therefore, the incorporation of proteomics into cardiovascular research will provide a means of exploring the mechanisms of disease onset and progression. This will in turn ultimately lead to increased efficiency of diagnosis and/or monitoring of treatment, which could dramatically increase the ability of the clinician to recognize cardiovascular disease states at a relatively early stage, and to improve the therapeutic approach
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Method and apparatus for authomatic delay compensation in space diversity radio transmissions
No full textAlgorithm for authomatic compensation of the difference of delay in diversity radio systems
Method and application for automatic delay compensation in space diversity radio transmission
No full textAlgorithm for authomatic compensation of the difference of delay in diversity radio systems
The secretome of endothelial cell: a tool for the study of the pleiotropic effects of statins
No full textThe clinical benefits of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are strongly related to their low density lipoprotein-cholesterol lowering properties. However, because mevalonic acid, the product of HMG-CoA reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects. Indeed, a variety of experimental data indicates that statins can interfere with major events involved in the formation of atherosclerotic lesions, independent of their hypocholesterolemic properties, although these effects have not been fully elucidated. In this respect, the application of a global proteomic approach to determine the effect of statins on the proteins released, “secretome”, by endothelial cells could help to understand novel mechanisms by which statins promote some of their beneficial effects. Two methods were applied to the identification and quantification of proteins differentially regulated by statins: a “gel based method” employing 2-DE, which can offer the additional advantage to distinguish between proteins isoforms as well as different post-translationally modified forms of the same proteins, and a “gel-free MS-based method” for “label-free” quantitation, which provided absolute quantitative profiling of proteins. The results coming from the application of both approaches were integrated, validated by biochemical assays, and allowed us to fully characterize the secretome of endothelial cells and to identify the drug-regulated proteins. In conclusion, secretomes are a rich source of new therapeutics and drug targets, and have the potential to become a major focus of drug discovery programs throughout the industry.
Funding: EC, FP6, LIFESCIHEALTH-contract n° LSHM-CT-2007-037273-PROCARDI
- …
